

on) an alternative concentration of 3.7 ppt TEQ in residential soil and 17 ppt TEQ in commercial/industrial soil as draft interim PRGs. These alternative draft interim PRGs would be protective for cancer and non-cancer effects and are consistent with the NCP provision for PRGs reflecting a 1E-06 risk level as a point of departure for determining remediation goals. OSWER notes that PRGs based on a 1E-06 cancer risk level would likely be within or possibly below the average concentration of dioxins in rural U.S. soils. Generally, it is OSWER's policy not to clean below background (for more information about this policy visit <http://cfpub.epa.gov/ncea/CFM/recorisplay.cfm?deid=150944>).

Dated: December 30, 2009.
Mathy Stanislaus,
Assistant Administrator, Office of Solid Waste and Emergency Response.
 [FR Doc. 2010-16 Filed 1-6-10; 8:45 am]
BILLING CODE 6560-50-P

Commission and the Assistant Attorney General advance notice and to wait designated periods before consummation of such plans. Section 7A(b)(2) of the Act permits the agencies, in individual cases, to terminate this waiting period prior to its expiration and requires that notice of this action be published in the **Federal Register**.

FEDERAL TRADE COMMISSION

Granting of Request for Early Termination of the Waiting Period Under the Premerger Notification Rules

Section 7A of the Clayton Act, 15 U.S.C. 18a, as added by Title II of the Hart-Scott Rodino Antitrust Improvements Act of 1976, requires persons contemplating certain mergers or acquisitions to give the Federal Trade

The following transactions were granted early termination of the waiting period provided by law and the premerger notification rules. The grants were made by the Federal Trade Commission and the Assistant Attorney General for the Antitrust Division of the Department of Justice. Neither agency intends to take any action with respect to these proposed acquisitions during the applicable waiting period.

TRANSACTION GRANTED EARLY TERMINATION

ET date	Trans No.	ET req status	Party name
02-NOV-09	20100028	G	Compuware Corporation.
		G	Gomez, Inc.
		G	Gomez, Inc.
03-NOV-09	20100047	G	J&F Participacoes S.A.
		G	Controlling Holding.
		G	Controlling Holding.
	20100052	G	H.I.G. Bayside Debt and LBO Fund II, L.P.
		G	Dr. Rodolfo Gari and Mrs. Laurie Gari.
		G	Business IT Solutions of Tampa, Inc.
		G	Medical Billing Solutions, LLC.
		G	Sarasota Anesthesia Services, LLC.
		G	Surgery Partners of Coral Gables, LLC.
		G	Armenia Surgery Center, Inc.
		G	APS of Merritt Island, LLC.
		G	APS of Bradenton, LLC.
		G	Anesthesia Professional Services, Inc.
		G	Anesthesia Management Services, LLC.
		G	Surgery Partners of Lake Mary, LLC.
		G	Weschase Anesthesiology Professional Services, Inc.
		G	Tampa Pain Relief Center, Inc.
		G	Surgery Partners, LLC.
		G	Surgery Partners of Lake Worth, LLC.
		G	Surgery Partners of Merritt Island, LLC.
		G	Surgery Partners of Millenia, LLC.
		G	Surgery Partners of New Tampa, LLC.
		G	Surgery Partners of Park Place, LLC.
		G	Surgery Partners of Sarasota, LLC.
		G	Surgery Partners of Westchase, LLC.
		G	Surgery Partners of West Kendall, L.L.C.
	20100057	G	Berkshire Hathaway Inc.
		G	Capmark Financial Group Inc.
		G	Capmark Capital Inc.
		G	Capmark Finance Inc.
04-NOV-09	20100017	G	Rohm Co., Ltd.
		G	Kionix, Inc.
		G	Kionix, Inc.
	20100053	G	Occidental Petroleum Corporation.
		G	Citigroup Inc.
		G	Phibro, LLC.
05-NOV-09	20100058	G	Leucadia National Corporation.
		G	Capmark Financial Group Inc.
		G	Capmark Capital Inc.
		G	Capmark Finance Inc.
06-NOV-09	20100078	G	Kok Thay Lim.
		G	Empire Resorts, Inc.
		G	Empire Resorts, Inc.
	20100081	G	Carlyle Partners V L.P.
		G	TA IX L.P.

TRANSACTION GRANTED EARLY TERMINATION—Continued

ET date	Trans No.	ET req status	Party name	
09-NOV-09	20100082	G	OpenLink Financial, Inc.	
		G	Dollar Financial Corp.	
		G	The CVRF Trust.	
	20090760	G	Military Financial Services, LLC.	
		G	CA, Inc.	
		G	NetQoS, Inc.	
	20100040	G	NetQoS, Inc.	
		G	Riverside Capital Appreciation Fund V, L.P.	
		G	Precision Wire Components, LLC.	
	20100050	G	Precision Wire Components, LLC.	
		G	FPL Group Limited.	
		G	Babcock & Brown Limited (Liquidators Appointed).	
	20100054	G	Babcock & Brown Limited (Liquidators Appointed).	
		G	Ciena Corporation.	
		G	Nortel Networks Corporation.	
20100064	G	Nortel Networks Corporation.		
	G	GSI Commerce, Inc.		
	G	Retail Convergence, Inc.		
20100071	G	Retail Convergence, Inc.		
	G	Integrated Solutions, LLC.		
	G	Coleman Technologies, Inc.		
20100073	G	Coleman Technologies, Inc.		
	G	Invesco Ltd.		
	G	Morgan Stanley.		
20100074	G	Van Kampen Investments, Inc.		
	G	Morgan Stanley.		
	G	Invesco Ltd.		
20100080	G	Invesco Ltd.		
	G	Genstar Capital Partners V, L.P.		
	G	FHME Holdings, Inc.		
10-NOV-09	20090629	G	Florida Home Medical Equipment, Inc.	
		G	Sierra Holdings Corp.	
		G	Nortel Networks Corporation.	
	20100059	G	Nortel Networks Limited.	
		G	Nortel Government Solutions Incorporated.	
		G	DiamondWare Ltd.	
	20100083	G	NNC.	
		G	Nortel Networks, Inc.	
		G	Agropur Cooperative.	
	20100087	G	Sjerp W. Ysselstein.	
		G	Green Meadows Food, LLC.	
		G	Tellabs, Inc.	
	12-NOV-09	20100072	G	WiChorus, Inc.
			G	WiChorus, Inc.
			G	Steiner Leisure Limited.
20100075	G	Starwood Hotels and Resorts Worldwide, Inc.		
	G	Bliss World Holdings, Inc.		
	G	Bliss World LLC.		
16-NOV-09	20100076	G	EverBank Financial Corp.	
		G	Tygris Commercial Finance Group, Inc.	
		G	Tygris Commercial Finance Group, Inc.	
16-NOV-09	20100076	G	New Mountain Partners III, L.P.	
		G	EverBank Financial Corp.	
		G	EverBank Financial Corp.	
	20100101	G	TPG Partners VI, L.P.	
		G	EverBank Financial Corp.	
		G	EverBank Financial Corp.	
	20100105	G	Markit Group Holdings Limited.	
		G	Fidelity National Information Services, Inc.	
		G	Clear Par, LLC.	
	20100106	G	Fidelity Information Services, Inc.	
		G	Groupe Aeroplan Inc.	
		G	The Marilyn Carlson Nelson 1998 GST Family Trust.	
	20100110	G	Carlson Marketing Worldwide, Inc.	
		G	Groupe Aeroplan Inc.	
		G	The Barbara Carlson Gage 1998 GST Family Trust.	
20100112	G	Carlson Marketing Worldwide, Inc.		
	G	GS Capital Partners VI, L.P. G Compass Investors Inc.		
	G	Compass Investors Inc.		
		G	GS Capital Partners VI Offshore, L.P.	
		G	Compass Investors Inc.	

TRANSACTION GRANTED EARLY TERMINATION—Continued

ET date	Trans No.	ET req status	Party name	
17-NOV-09	20100115	G	Compass Investors Inc.	
		G	Adecco S.A.	
	20100116	G	MPS Group, Inc.	
		G	MPS Group, Inc.	
		G	Powdr Corp.	
		G	Intrawest Cayman L.P.	
		G	Copper Mountain Real Estate, Inc.	
		G	Wheeler Junction Electric Company.	
	19-NOV-09	20100044	G	CMH Corporation.
			G	Copper Mountain Inc.
20100086		G	Becton Dickinson and Company.	
		G	HandyLab, Inc.	
		G	HandyLab, Inc.	
		G	Cisco Systems, Inc.	
20100107		G	ScanSafe, Inc.	
		G	ScanSafe, Inc.	
		G	United Refining Energy Corp.	
		G	Chaparral Energy, Inc.	
	20100111	G	Chaparral Energy, Inc.	
		G	H.I.G. Bayside Debt& LBO Fund II, L.P.	
	20100048	G	Allion Healthcare, Inc.	
		G	Allion Healthcare, Inc.	
20100096		G	Abbott Laboratories.	
		G	Solvay SA.	
20100097		G	Sodufa BV.	
		G	Solvay Pharmaceuticals Marketing & Licensing AG.	
		G	MasTec, Inc.	
		G	Michael Daniel Murphy.	
20-NOV-09		20100125	G	Precision Transport Company, LLC.
			G	Precision Pipeline, LLC.
	20100126	G	Precision Pipeline, LLC.	
		G	MasTec, Inc.	
	20100068	G	Steven R. Rooney.	
		G	Precision Pipeline, LLC.	
		G	Precision Transport Company LLC.	
		G	Nippon Oil Corporation.	
	23-NOV-09	20100126	G	Nippon Mining Holdings, Inc.
			G	Nippon Mining Holdings, Inc.
20100068		G	Nippon Mining Holdings, Inc.	
		G	Nippon Oil Corporation.	
20100069		G	Nippon Oil Corporation.	
		G	Nippon Oil Corporation.	
		G	RehabCare Group, Inc.	
		G	TA IX L.P.	
24-NOV-09		20100084	G	Triumph HealthCare Holdings, Inc.
			G	TA IX L.P.
	20100122	G	RehabCare Group, Inc.	
		G	RehabCare Group, Inc.	
	20100133	G	MEMC Electronic Materials, Inc.	
		G	Sun Edison LLC.	
		G	Sun Edison LLC.	
		G	United Health Group Incorporated.	
	20090265	G	CareMedic Holdings, Inc.	
		G	CareMedic Holdings, Inc.	
20100135		G	Heilman & Friedman Capital Partners Vt, L.P.	
		G	Thoma Cressey Fund VII, L.P.	
20100061		G	Datatel Holdings, Inc.	
		G	Panasonic Corporation.	
	G	SANYO Electric Co., Ltd.		
	G	SANYO Electric Co., Ltd.		
20100062	G	GTCR Fund IX/A, L.P.		
	G	BIT Systems, Inc.		
	G	BIT Systems, Inc.		
	20100123	G	Advocate Health Care Network.	
		G	BroMenn Healthcare System.	
	20100062	G	BroMenn Healthcare Hospitals.	
G		BroMenn Physician Hospital Organization.		
G		BroMenn Physicians Management Corporation.		
G		BroMenn Foundation.		
20100062	G	Berry Plastics Group, Inc.		
	G	JPMorgan Chase & Co.		
20100123	G	Pliant Corporation.		
	G	Dassault Systemes.		

TRANSACTION GRANTED EARLY TERMINATION—Continued

ET date	Trans No.	ET req status	Party name
25–NOV–09	20100088	G	International Business Machines Corporation.
		G	International Business Machines Corporation.
		G	The Southern Company.
	20100089	G	Broadway Generating Company, LLC.
		G	West Georgia Generating Company, LLC.
		G	Broadway Generating Company, LLC.
		G	Southern Power Company.
		G	DeSoto County Generating Company, LLC.
		G	Ameriprise Financial, Inc.
	20100117	G	Bank of America Corporation.
		G	Bank of America, N.A.
		G	Columbia Wanger Asset Management, L.P.
G		WAM Acquisition GP, Inc.	
20100154		G	ACS Actividades de Construccion y Servicios, S.A.
		G	William R. Pulice.
	G	Pulice Construction, Inc.	
	G		
27–NOV–09	20100154	G	
		G	
		G	
		G	

For Further Information Contact:
Sandra M. Peay, Contact Representative
or Renee Hallman, Contact
Representative, Federal Trade
Commission, Premerger Notification
Office, Bureau of Competition, Room H–
303, Washington, DC 20580, (202) 326–
3100.

By Direction of the Commission.

Donald S. Clark,
Secretary.

[FR Doc. E9–31208 Filed 1–6–10; 8:45 am]

BILLING CODE 6750–01–M

DEPARTMENT OF HEALTH AND HUMAN SERVICES

National Institutes of Health

Government-Owned Inventions; Availability for Licensing

AGENCY: National Institutes of Health,
Public Health Service, HHS.

ACTION: Notice.

SUMMARY: The inventions listed below
are owned by an agency of the U.S.
Government and are available for
licensing in the U.S. in accordance with
35 U.S.C. 207 to achieve expeditious
commercialization of results of
federally-funded research and
development. Foreign patent
applications are filed on selected
inventions to extend market coverage
for companies and may also be available
for licensing.

ADDRESSES: Licensing information and
copies of the U.S. patent applications
listed below may be obtained by writing
to the indicated licensing contact at the
Office of Technology Transfer, National
Institutes of Health, 6011 Executive
Boulevard, Suite 325, Rockville,
Maryland 20852–3804; telephone: 301–

496–7057 fax: 301/402–0220. A signed
Confidential Disclosure Agreement will
be required to receive copies of the
patent applications.

Method of Preventing and Treating Metastatic Disease

Description of Technology: Cancer
that recurs as metastatic disease many
years after primary tumor resection and
adjuvant therapy appears to arise from
tumor cells that disseminated early in
the course of disease but did not
develop into clinically apparent lesions.
These long-term surviving,
disseminated tumor cells maintain a
state of dormancy, but may be triggered
to proliferate through largely unknown
factors. Inventors at the National
Institutes of Health have discovered
agents that prevent or treat recurrent
metastatic cancer by inhibiting type I
collagen production and downstream
signaling through beta 1 integrin
activation. Blocking activation of beta-1
integrin signaling using
pharmacological approaches or using
RNA interference was found to prevent
reorganization of the cytoskeleton that is
associated with proliferation of the
dormant tumor cells. The technology
provides compositions and methods for
modulating the switch from tumor cell
dormancy to proliferation clinical
metastatic disease in a patient by
administering beta-1 integrin signaling
inhibitors.

Applications

- Method of treating metastatic
disease by targeting components of the
beta-1 integrin signaling pathway.
- Method of preventing metastatic
disease after removal of primary tumors.

Advantage: Discovery of beta-1
integrin signaling pathway involvement
provides a number of therapeutic targets

for development of novel cancer
therapeutics.

Market: In the U.S., it is estimated
that 192,370 women will be diagnosed
with and 40,170 women will die of
cancer of the breast in 2009. Although
improved detection and treatment of
primary tumors has raised the rate of
survival there remains a high
probability of recurrence of metastatic
disease leading to mortality.

Inventors: Dalit Barkan and Jeffrey E.
Green (NCI).

Publications: None related to this
technology.

Patent Status: U.S. Provisional
Application No. 61/179,641 filed 19
May 2009 (HHS Reference No. E–192–
2009/0–US–01).

Licensing Status: Available for
licensing.

Licensing Contact: Surekha Vathyam,
PhD, 301–435–4076;
vathyams@mail.nih.gov.

Collaborative Research Opportunity:
The Center for Cancer Research,
Laboratory of Cancer Biology and
Genetics, is seeking statements of
capability or interest from parties
interested in collaborative research to
further develop, evaluate, or
commercialize this technology. Please
contact John D. Hewes, PhD at 301–435–
3121 or hewesj@mail.nih.gov for more
information.

Diamidine Inhibitors of Tdp1 as Anti- Cancer Agents

Description of Technology: Available
for licensing and commercial
development are methods and
compositions for treating cancer, using
novel compounds derived from
diamidine. Diamidine and its
derivatives are potent inhibitors of
tyrosyl-DNA-phosphodiesterase (Tdp1),
which may be useful in chemotherapy.